Compound ID | 895
ABI-0197N
Class: Rifamycin
| Agent Type: | Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | RNA synthesis inhibitor |
| Target Pathogen: | Active against methicillin-resistant Staphylococcus aureus |
| Description: | Rothstein DM, Mullin S, Sirokman K, Hazlett C, Doye A, et al. Novel rifamycin derivatives possess good in vivo efficacy in a rifamycin-resistant S. aureus infection model. 44th-ICAAC 2004;206-208 |
| Institute where first reported: | ActivBiotics, Inc., USA |
| Year first mentioned: | 2004 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/349988029 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.